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Healthcare safety and quality surveillance is increasingly conducted by public health agencies. We describe a biomedical informatics
method that uses multiple public health data sources to perform surveillance of methadone-related adverse drug events. Data from Utah
medical examiner records, vital statistics, emergency department encounter administrative data and a database of controlled substances
prescriptions are used to examine trends in state-wide adverse events related to methadone. From 1997 to 2004, population-adjusted
methadone prescriptions increased 727%, with evidence to suggest the rise in the methadone prescription rate is for treatment of pain,
not addiction therapy. During the same period of time, population adjusted, accidental methadone-related deaths in medical examiner
data increased 1770%. Population adjusted methadone-related emergency department encounters rose 612% from 1997 to 2003. Our
results suggest that the increase in methadone prescription rates from 1997 to 2004 was accompanied by a concurrent increase in meth-
adone-related morbidity and mortality. Although patient data is not linked between data sources, our results demonstrate that utilizing
multiple public health data sources captures more cases and provides more clinical detail than individual data sources alone. Our
approach is a successful biomedical informatics approach for surveillance of adverse events and utilizes widely available public health
data sources, as well as an emerging source of public health data, controlled substance prescription registries.
 2006 Elsevier Inc. All rights reserved.
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Unintentional fatalities due to prescription medications
are an increasing problem in the United States and Utah
[1]. For the years 1999–2003, unintentional deaths due to
prescription medications were the fourth-leading cause of
death in 25–54 year olds in Utah (Barry Nangle, PhD. Per-
sonal communication, 8/31/2004). A recent study of Utah
medical examiner data found deaths of unintentional or
undetermined intent caused by prescription medications
increased from 1.5/100,000 residents (1991–1998) to 4.4/
100,000 residents (1999–2003). Methadone was the most1532-0464/$ - see front matter  2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.jbi.2006.10.004
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E-mail address: shannon.sims@hsc.utah.edu (S.A. Sims).common drug identiﬁed by the Utah medical examiner as
causing or contributing to accidental deaths for 2003–
2005. Notably, while deaths of unintentional or undeter-
mined intent caused by prescribable narcotics nearly tri-
pled, cases of self-inﬂicted harm (suicide) with those
drugs remained stable from 1991 to 2003 [2]. In addition
to the medical examiner data, retail supply data from the
United States Drug Enforcement Administration (DEA)
shows a sharp increase in the amount of methadone distrib-
uted in Utah since 1999 [3]. The medical examiner and
DEA data suggest methadone prescription rates and meth-
adone-related deaths are both rising in Utah, but more
research is necessary to conﬁrm this ﬁnding.
Methadone may be prone to cause serious harm and
death for several reasons. Historically, methadone has
been used to treat chronic abuse of opiates such as heroin.
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ingly prescribed for acute and chronic pain [4]. Methadone
may pose patient safety concerns because of its highly var-
iable half life, 16–100 h, and variable potency with chronic
opiate users. Additionally, methadone may be more likely
to cause harm than other pain medications due to physi-
cian inexperience titrating a safe, eﬀective dose; lack of
clear evidence for appropriate use; and the risk of delayed
overdose [4,5].
To study methadone-related harm in Utah, we adopt an
informatics approach that utilizes data from multiple pub-
lic health data sources to examine concurrent trends in
methadone-related morbidity and mortality and metha-
done prescription rates. Our ﬁrst objective is to determine
whether broader examination of available public health
data corroborate the ﬁnding from medical examiner and
DEA data that methadone-related deaths and prescriptions
are trending upward for the past eight years. We also seek
to determine trends in serious methadone-related adverse
events requiring an emergency department encounter; i.e.,
those cases in which death is not the initial medical presen-
tation. Our second objective is to demonstrate the value of
utilizing commonly available public health data sources for
surveillance of adverse events, though the patient data is
not linked between sources.
Public health surveillance of adverse events diﬀers
from patient-level clinical surveillance. Both seek to
quantify, analyze and ultimately prevent adverse events;
however, clinical informatics surveillance focuses on the
individual and has ready access to data not always avail-
able to public health practitioners. The clinical informat-
ics literature has documented the value of utilizing
multiple data sources to capture the largest fraction of
actual adverse events and the most information about
those patient-level events. Published data sources for
clinical informatics surveillance of adverse drug events
include inpatient pharmacy data, laboratory data and
natural language understanding examination of provider
notes [6]. We examine the utility of extending a multiple
data source surveillance approach to commonly available
public health data sources and focusing on population-
level data rather than individuals.Table 1
Public health data source descriptions
Data source Years
examined
Coding ontology
Controlled substances
database
1997–2004 Drug data is encoded with National
Drug Code number and ingredient
Medical examiner data 1997–2004 Free text
Death certiﬁcate data 1999–2004 Primary and secondary cause of dea
are encoded with ICD-10a
Emergency department
encounter database
1997–2003 Diagnosis data is encoded with ICD
CMb
a World Health Organization’s International Classiﬁcation of Diseases, Rev
b Centers for Medicaid and Medicare’s International Classiﬁcation of Disea2. Data sources
For our analysis, we use methadone prescription data
from Utah’s controlled substances registry, methadone-re-
lated death data from vital statistics and medical examiner
data and methadone-related emergency department
encounters from the Utah Emergency Department
Encounter Database (Table 1).
2.1. Utah Controlled Substances Database
The Utah Controlled Substances Database (CSDB) is a
registry enacted by legislative mandate (Utah Code Section
57-37-7.5) to track all outpatient prescriptions for Schedule
II–V drugs dispensed in Utah and by Utah providers. In
use since 1995, Utah’s registry is the oldest controlled sub-
stances registry in the United States. All retail, institutional
and mail order pharmacies in Utah that dispense prescrip-
tions for Schedule II–V drugs are required to report; how-
ever, inpatient facilities do not submit data [7]. The
Division of Occupational and Professional Licensing with-
in the Utah Department of Commerce maintains the
CSDB.
Pharmacies report seventeen variables to the CSDB
from pharmacies: pharmacy identiﬁcation number, name,
address, birth date and sex of prescription holder, date
ﬁlled, prescription number, new/reﬁll code, metric quantity
of drug, days supply of drug, National Drug Code Num-
ber, prescriber identiﬁcation number, date the prescription
was written and number of reﬁlls authorized.
2.2. Utah medical examiner data
Utah has a state-wide, centralized medical examiner sys-
tem that has statutorily mandated jurisdiction over all
deaths thought to be drug-related [8]. Case information
for methadone-related deaths is taken from the Oﬃce of
the State Medical Examiner’s (ME) database. The ME
database contains 113 variables including demographic
information about the decedent, toxicological, laboratory
and autopsy examination results. Cause of death ascertain-
ment is supervised by a physician examiner using allCase selection criteria
Prescription for methadone
Decedents from Utah with methadone included as a drug causing or
contributing to death AND manner of death is not suicide
th Decedents from Utah with secondary cause of death code due to
methadone AND primary cause of death is not suicide
-9- Patients with diagnosis code(s) for methadone-related harm AND no
code(s) for intentional harm to self
ision 10.
ses, Revision 9, Clinical Modiﬁcation.
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circumstances of death, physical examination, laboratory
data, and medical records.
2.3. Utah vital statistics data
Death certiﬁcate data is a component of vital statistics
information maintained by the Oﬃce of Vital Records
and Statistics at the Utah Department of Health (UDOH).
Each death certiﬁcate has a primary cause of death ﬁeld
and up to nine contributing diagnosis ﬁelds. Deaths for
1997 and 1998 are coded using the World Health Organiza-
tion’s International Classiﬁcation of Diseases, Ninth Revi-
sion (ICD-9). ICD, Tenth Revision (ICD-10) is used for
deaths after 1998. ICD-9 diﬀers substantially from ICD-
10. ICD-10 has approximately twice as many codes, allows
greater speciﬁcity and does not have one-to-one matches
with all ICD-9 codes. Thus, comparing mortality trends
from years utilizing diﬀerent versions of the ICD coding
system is challenging and must be done cautiously [9,10].
In addition to concerns with cross-walking between ICD-
9 and ICD-10, there are technical diﬃculties with the
1997–1998 data that limit analysis. Therefore, death certif-
icate data from the years 1997–1998 are excluded from our
analysis.
2.4. Utah emergency department encounter database
The Emergency Department Encounter Database
(EDED) is a repository of all emergency department
patient encounters in Utah and is maintained by the
Bureau of Emergency Medical Services at the UDOH.
Utah administrative rule R426-1-7 mandates that all
licensed Utah hospitals report information on emergency
department patient encounters to the EDED. The data-
base contains complete administrative (claims) data for
each encounter including diagnosis codes, procedure
codes, patient demographic information, services received
and hospital charges. For 1997–2003, diagnosis and pro-
cedure information is encoded with the Centers for
Medicare and Medicaid Services’ International Classiﬁca-
tion of Diseases, Ninth Revision, Clinical Modiﬁcation
(ICD-9-CM) [11]. Data from 2004 is not available for
this study.
3. Methods
Our study concurrently analyzes the CSDB for metha-
done prescriptions and the remaining three data sources
for methadone-related morbidity and mortality. However,
we do not link data across the four data sources for legal,
political and technical reasons. Access to study the CSDB
was granted to UDOH researchers only after lobbying
the Utah legislature to amend the CSDB statute. Our study
is a prudent ﬁrst use of the CSDB data and we aim to dem-
onstrate the potential value of additional informatics work
to link CSDB prescription data to morbidity and mortalitydata. A technical limitation to record matching is the lack
of a single patient identiﬁer across all the data sources.
However, some combinations of data sources have linking
identiﬁers and all data sources have demographic data that
can be used by record matching algorithms. For this rea-
son, linking patient records across all four data sources is
viable in the future, though the usual concerns with record
matching algorithm accuracy will apply [12,13].
3.1. Methadone prescription rates and demographic
characteristics of prescription recipients
We use all CSDB records from 1997–2004 and group the
data by calendar year. We identify methadone prescription
records by searching the ‘ingredient name’ ﬁeld for entries
that include the character string ‘methadone.’ We report
the total number of methadone prescriptions per year,
since the number of individual patients and prescribers
cannot be identiﬁed due to incompleteness of the CSDB
data and the de-identiﬁed data set used for this study.
Methadone prescription records are analyzed for patient
age and sex, as well as temporal and geographic variables.
For all data sources, we deﬁne urban according to the
UDOH convention: residence in Salt Lake, Davis, UT or
Weber counties. Signiﬁcance testing for diﬀerences in
demographic characteristics between data sources is done
using the unpaired t-test.
3.2. Medical examiner methadone-related death rates and
demographic characteristics
We use ME database records from 1997 to 2004 for
Utah residents with drug poisoning listed as cause of death.
The manner of death is classiﬁed by the medical examiner
as intentional (i.e., suicide or homicide); unintentional (i.e.,
accidental or natural deaths); or of undetermined intent.
From this larger group of drug poisoning deaths, we select
only cases with methadone included as a drug causing or
contributing to death and exclude cases classiﬁed as inten-
tional injuries (suicides). We exclude suicides because self-
inﬂicted injuries involve a separate approach to evaluation
and prevention. We determine the annual numbers and
rates of drug-poisoning deaths, trends in methadone-relat-
ed deaths over time and the demographic characteristics of
the patients.
3.3. Vital statistics methadone-related death rates and
demographic characteristics
Our study draws on complete, state-wide death certiﬁ-
cate data for the years 1999–2004, during which time
ICD-10 encodes causes of death. We select cases with
ICD-10 code T40.3, ‘Poisoning by Methadone,’ as a cause
of death. Since ICD-10 ‘T’ codes cannot be a primary cause
of death, all cases have the T40.3 code in one of the
contributing cause of death ﬁelds. We exclude cases with
suicide listed as the primary cause of death (ICD-10 codes
Fig. 1. Rate of methadone prescriptions, non-suicide methadone-related
deaths and non-suicide methadone-related emergency department encoun-
ters in Utah, 1997–2004.
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determine the number of deaths per year, trends in metha-
done-related deaths over time, demographic characteristics
of the decedents and the primary causes of death associated
with methadone-related deaths.
3.4. Emergency department encounters with methadone-
related diagnoses
We use EDED data for the years 1997–2003 and identify
records with ICD-9-CM codes speciﬁc for methadone-re-
lated harm using the following codes: 965.02, ‘poisoning
by methadone;’ E850.1, ‘accidental poisoning by metha-
done;’ and E935.1, ‘methadone causing adverse eﬀects in
therapeutic use.’ We select cases in which one or more of
the three methadone-related codes are present and self-in-
ﬂicted harm is not coded in the primary or secondary diag-
noses ﬁelds. The EDED records are grouped by calendar
year and we determine trends in methadone-related visits,
demographic characteristics of patients, patient discharge
status, charges associated with the encounter and the pri-
mary payor (insurer).
3.5. Institutional review board approval
Institutional Review Board approval was granted to
conduct this study at the UDOH (#104, approved January
20, 2005) and the University of Utah (#15641, approved
December 1, 2005). Our study was deemed exempt from
human subject regulatory oversight.
4. Results
Our investigation shows a parallel increase in metha-
done prescriptions and methadone-related morbidity and
mortality for the study period (Fig. 1; note: the y-axis for
the graph of prescription data diﬀers from the graphs of
death and emergency department data). The number of pre-
scriptions and harmful methadone-related events rises out
of proportion to the growth of the Utah population in all
data sources (Table 2).
4.1. Methadone prescriptions
The annual number of population-adjusted methadone
prescriptions in the Utah CSDB rose from 256.5 (1997)
to 2,120.1 (2004) per 100,000 population (Fig. 1), a 727%
increase. The total number of prescriptions rose from
5385 (1997) to 52,350 (2004) (Table 2). Of note, these ﬁg-
ures represent total prescriptions ﬁlled, not the number of
individuals with prescriptions; however, no change in pre-
scription regulations or reporting guidelines occurred dur-
ing study period to explain the dramatic increase. For
1997–2004, the mean age and gender distribution of indi-
viduals with methadone prescriptions varied little (age
range = 49.2–50.1 years); the percentage of prescriptions
to females ranged from 52.8 to 56.1%; and the percentageof prescriptions for residents of urban counties was 80.7–
84.4% (Table 3).
4.2. Medical examiner deaths
In medical examiner data, the number of methadone-
related non-suicide deaths per 100,000 Utah population
rose from 0.24 (1997) to 4.45 (2004) (Fig. 1), a 1770%
increase. The total number of deaths increased from 5
(1997) to 110 (2004) (Table 2). The mean age of dece-
dents ranged from 34.2 to 42.0 years; the percentage of
female decedents ranged from 31.3 to 60.0%; and the
percentage of decedents from urban counties was 70.0–
85.7% (Table 3).
Table 2
Data source record counts and Utah population data
Data source Record type 1997 1998 1999 2000 2001 2002 2003 2004
Controlled substances
database
Methadone
prescriptions
5,385 8,954 15,752 20,738 26,527 34,481 44,441 52,350
Total controlled
substance prescriptions
2,069,340 2,054,063 2,544,875 2,685,006 2,918,051 3,183,808 3,417,084 3,450,281
Medical examiner
(ME)
Methadone-related
deaths
5 7 16 20 35 59 86 110
Total ME cases 1,825 1,892 1,896 1,760 1,714 1,894 1,796 1,733
Death certiﬁcates Methadone-related
deaths
a a 17 25 37 58 81 107
Total death certiﬁcate
records
a a 11,978 12,335 12,604 13,040 13,339 13,268
Emergency department
(ED) encounters
Methadone-related
encounters
21 19 53 68 92 143 172 a
Total ED encounters 504,706 501,348 605,912 631,066 669,698 692,190 715,400 a
Utah population Residents 2,099,404 2,141,619 2,193,006 2,246,553 2,305,652 2,358,330 2,413,618 2,469,230
*Excludes self-inﬂicted injuries and suicides.
a Data not available.
Table 3
Demographic characteristics of methadone-related records in Utah Controlled Substances Database (CSDB), Medical Examiner Data (ME), Death
Certiﬁcates (DC) and Emergency Department Encounter Database (EDED), 1997–2004
Mean Age % Female % Urban
CSDB ME DC EDED CSDB ME DC EDED CSDB ME DC EDED
1997 49.6 36.2 a 31.0 53.6 60.0 a 70.0 83.6 80.0 a 61.9
1998 50.1 42.0 a 35.3 52.8 42.9 a 47.4 83.5 85.7 a 85.0
1999 49.7 38.4 38.3 41.0 55.6 31.3 29.4 46.0 84.4 81.3 76.5 88.7
2000 49.6 34.2 35.4 41.0 56.1 40.0 44.0 56.1 84.4 70.0 76.0 72.1
2001 49.5 40.3 40.2 42.8 55.6 48.6 40.5 64.8 83.3 82.9 81.1 78.3
2002 49.6 37.7 38.5 43.4 54.8 33.9 34.5 57.3 81.4 74.6 74.1 82.5
2003 49.8 38.3 38.3 40.7 54.2 46.5 43.2 55.9 80.8 70.9 67.9 79.1
2004 49.2 37.4 37.9 a 53.8 32.7 35.5 a 80.7 80.9 80.4 a
Average 49.1 38.4 38.1 39.3 54.6 42.0 37.9 56.8 82.8 78.3 76.0 78.2
a Data not available.
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In death certiﬁcate data, the number of non-suicide
records where methadone was a contributing factor rose
from 0.78 (1999) to 4.33 (2004) per 100,000 Utah population
(Fig. 1). The absolute number of methadone-related deaths
increased from 17 (1999) to 107 (2004) (Table 2). During
the same time period, themean age of decedents ranged from
35.4 to 40.2 years; the percentage of female decedents ranged
from 29.4 to 44.0%; and the percentage of decedents from
urban counties was 67.9–81.1% (Table 3). In 97.4% of cases,
the primary ICD-10diagnosis codewasdrugpoisoning (acci-
dental or undetermined intent) or mental/behavioral disor-
der related to prescribable medications or illicit drugs. In
2.6% of the cases, a non-drug-related cause of death (e.g.
obesity or cardiac myopathy) was the primary diagnosis.
4.4. Emergency department encounters
Emergency department encounters with non-suicide
methadone-related diagnoses increased from 1.0 (1997) to7.1 (2003) per 100,000 Utah population (Fig. 1), a 612%
increase. The absolute number of emergency department
encounters rose from 21 (1997) to 172 (2003); 2004 data
not available (Table 2). The mean age of patients with
emergency department encounters from 1997 to 2003 ran-
ged from 31.0 to 43.4 years; the percentage of female
patients varied from 46.0 to 70.0%; and the percentage of
encounters with patients from urban counties was
61.9–82.5% (Table 3).
For methadone-related encounters, the patient disposi-
tion was most commonly discharged to home
(76.9–100%); admission to the hospital or other healthcare
facility was the next most frequent disposition (0–20.3%);
and death in the emergency department occurred rarely
(0–5.0%). The primary type of payor was a private insurer
in 25.0–48.9% of cases. Medicare, Medicaid, or other gov-
ernment source was the primary payor in 23.8–50.9% of
cases. Average hospital charges for methadone-related
emergency department encounters rose from $622 in 1997
to $6622 in 2003; the average hospital charges in the EDED
for all 2003 ED visits were $1970. The sum of all costs for
Table 4
Descriptive data for methadone-related emergency department encounters in Utah, 1997–2004
ED Discharge Status Primary payor (insurer) Total charges for ED visit
Healthcare facility Home Death Othera Private Gov’tb Otherc Sum all cases Avg/case
1997 (n = 21) 0% 100% 0% 0% 38.1% 23.8% 38.1% $13,058 $622
1998 (n = 19) 10.0% 85.0% 5.0% 0% 25.0% 45.0% 30.0% $18,756 $938
1999 (n = 53) 17.0% 79.2% 1.9% 1.9% 35.8% 50.9% 13.2% $238,706 $4504
2000 (n = 68) 14.7% 77.9% 1.5% 5.9% 42.6% 47.1% 10.3% $329,293 $4843
2001 (n = 92) 13.0% 85.9% 0% 1.1% 48.9% 32.6% 18.5% $513,000 $5576
2002 (n = 143) 20.3% 76.9% 0.7% 2.1% 32.9% 43.4% 23.8% $933,893 $6531
2003 (n = 172) 19.2% 76.7% 1.2% 2.9% 33.1% 47.1% 19.8% $1,138,953 $6622
a Against medical advice, unknown, other.
b Medicare, Medicaid, other government payor.
c Charity, self-pay, unknown.
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increased from $13,058 in 1997 to $1,138,953 in 2003
(Table 4).
5. Discussion
Surveillance of healthcare safety and quality is increas-
ingly becoming the domain of public health agencies. In
Utah, for example, the legislature mandated that the
UDOH publish annual reports on the quality and safety
of obstetrical care provided at the state’s healthcare institu-
tions [14]. Public health practitioners have access to a
broad range of public health and clinical data resources
to draw upon when surveillance is needed. Unfortunately,
many of these data sources are in diﬀerent systems and
can lack uniformity in available data, data quality, data
completeness, data encoding and cross-system unique
identiﬁers. Information technology tools are available to
perform speciﬁc types of safety and quality surveillance
[15–17], but not all surveillance needs are met by existing
tools.
We demonstrate the utility of applying a biomedical
informatics approach from patient-level clinical informat-
ics to the public health domain. Concurrently analyzing
multiple public health data sources for evidence of morbid-
ity and mortality due to adverse events can be a useful tech-
nique for surveillance of population trends, particularly
when data linkage between data sources is not possible
for technical, ﬁnancial, temporal or legal reasons. Our mul-
tiple data source approach captures a broader range of
events and provides more clinical detail than a single data
source. Although each data source has limitations, aggre-
gate data analysis can provide more comprehensive mor-
bidity and mortality data.
Our study also demonstrates the value of an important
and emerging source of surveillance data, the controlled
substance prescription registry. In Utah, pharmacies are
required to report outpatient prescriptions ﬁlled for con-
trolled substances to the state. Since prescription data are
frequently a missing piece of data in surveillance, con-
trolled substance prescription registries oﬀer a powerful
source of information for studying controlled substance
adverse events. Utah has the oldest such registry, butcontrolled substances registries were enacted in twenty-six
states by the end of 2005, according to the Drug Enforce-
ment Agency, Oﬃce of Diversion Control [18]. Our study
represents an early model for the eﬀective use of controlled
substance prescription data for surveillance of healthcare
safety and quality. Concurrent use of controlled substances
prescription data and morbidity and mortality data sources
has broad applicability since medical examiner, vital statis-
tics and emergency department encounter data are widely
available.
We apply this public health informatics surveillance
methodology to examine adverse events due to methadone
in Utah. Using population adjusted data, methadone pre-
scriptions rose 727% from 1997 to 2004. During the same
period of time, population adjusted cases of non-suicide,
methadone-related deaths increased 1770% in medical
examiner data. Similarly, methadone-related emergency
department encounters rose by 612% from 1997 to 2003
(2004 data not available). Death certiﬁcate data also
showed an upward trend from 1999 to 2004 (1997–1998
data are not available for comparison). Our ecologic study
demonstrates parallel trends of increasing methadone pre-
scriptions, increasing accidental methadone deaths and
increasing methadone-related emergency department visits.
Medical examiner data shows an increase in accidental
deaths due to methadone that is substantially greater than
the increase in methadone prescriptions.
In Utah, there are several reasons to suspect that the
steep rise in methadone prescriptions from 1997 to 2004
is largely due to treatment of pain. The rate of heroin abuse
and admissions for opiate addiction to substance abuse
treatment facilities in Utah is unchanged during the study
period, 1997–2004 [19]. Utah code dictates that physicians
may not prescribe methadone for addiction therapy unless
they are directly aﬃliated with an addiction treatment facil-
ity. Additionally, methadone data from addiction treat-
ment facilities is not included in retail pharmacy data
reported by the DEA and addiction treatment facilities
are exempt from reporting data to the Utah CSDB. All
of these factors suggest the dramatically increased number
of methadone prescriptions and the increased retail supply
of drugs are for individuals using methadone for pain ther-
apy, rather than addiction therapy. Our data sources do
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patients is chronic drug abusers. However, amongst the
population of patients using methadone for pain manage-
ment, a substantial portion of harm and death is likely to
be accidental and not associated with chronic drug abuse.
The demographic characteristics of individuals harmed
by methadone are signiﬁcantly diﬀerent from those receiv-
ing methadone prescriptions in two ways. First, the mean
age of individuals from medical examiner, death certiﬁcate
and emergency room encounter data ranges from 38.1 to
39.3 years old; in contrast, the mean age of age of individ-
uals with methadone prescriptions is signiﬁcantly (p < 0.
01) higher at 49.1 years old. Second, the percentage of
males dying from methadone-related harm is signiﬁcantly
(p < 0.01) higher than those receiving prescriptions; 58.0%
male decedents in the medical examiner data and 62.1%
male decedents in the death certiﬁcate data. In the
controlled substances prescription data, only 45.4% of pre-
scriptions were for males. The younger and predominantly
male nature of decedents and the younger age of emergency
department encounters may reﬂect diﬀerential health-seek-
ing behaviors of older individuals and female patients.
Alternatively, the demographic diﬀerence may be due to
the subset of our study population who are drug abusers.
Drug abusers are more likely to be young and male [19];
they may be more prone to death for a variety of reasons.
However, more research is necessary to fully understand
the demographic and clinical factors that contribute to
the diﬀerences in deaths and emergency department visits.
Our data also suggest the cost of healthcare encounters
associated with methadone-related harm is rising. Charges
associated with methadone-related emergency department
encounters show an escalating pattern of cost per patient
and total charges for all patients. From 1997 to 2003, both
the total cost and average cost per patient increased steadi-
ly. The total cost of all methadone-related emergency
department encounters increased greater than eighty-fold
from $13,058 in 1997 to $1,138,953 in 2003. We do not
attempt to capture less serious events that require outpa-
tient management only, the follow-up care required for
emergency department visits, or healthcare costs associated
with deaths. Thus, our data represent only a fraction of the
ﬁnancial burden caused methadone-related harm, much of
which is paid for by government payors.
Our study has some limitations. The ecologic study
design does not allow us to designate a causal relationship
between increasing methadone prescriptions and harm.
Possible confounding factors include the unknown fraction
of drug abusers in our population, the unknown portion of
individuals who received prescription medication from illic-
it sources, and the unknown fraction of prescription
records that represent unique individuals who received
methadone prescriptions. We were unable to utilize
1997–1998 vital statistics data due to technical concerns
and the shift in coding terminologies from ICD-9 to
ICD-10. Additionally, the controlled substances database,
vital statistics and emergency department encounter datasources have inconsistencies in completeness and coding
practices over the study period. ICD-9-CM coding is a lim-
iting factor, both for determining the intent of an injury
and overall concern with the validity of administrative data
for clinical purposes [20].
The next step in examining methadone-related harm is
linking patient data across the data sources. Data linkage
will allow us to determine if a causal relationship exists
between increasing methadone prescription rates and meth-
adone-related morbidity and mortality. The informatics
challenges associated with data linkage, however, are sub-
stantial. Record-matching across the data sources is techni-
cally diﬃcult since there is no unique identiﬁer across all
record sources and our investigation shows large gaps in
demographic data and completeness of the Utah CSDB
necessary for algorithmic record-matching. In addition,
access to the controlled substances registry is tightly regu-
lated by Utah statute and politically charged because of
concerns with patient privacy. Data linkage eﬀorts will
need to carefully balance protecting privacy with gathering
the data necessary to further study this issue. Despite the
technical and political challenges, data linkage oﬀers great
promise to better understand methadone-related adverse
events. Critical clinical details such as the time from meth-
adone prescription to harm and the health characteristics
of harmed individuals can be better studied. Finally, estab-
lishing a deﬁnitive relationship between prescribing metha-
done for pain and harm will shape the public health
response. Possible interventions include eﬀorts to educate
healthcare consumers and clinicians and, if the evidence
warrants, regulatory action to limit methadone prescrip-
tion privileges to appropriately trained physicians.
6. Conclusion
Concurrent analysis of multiple public health data sourc-
es fromUtah demonstrates a trend of increasing methadone
prescriptions, methadone-related deaths and serious metha-
done-related events requiring emergency department treat-
ment. Although patient data is not linked between data
sources, our results demonstrate that utilizing multiple pub-
lic health data sources captures more adverse event infor-
mation and provides more clinical detail than individual
data sources alone. Our approach is a widely applicable,
successful biomedical informatics approach for surveillance
of adverse events and utilizes commonly available public
health data sources, as well as an emerging source of public
health data, controlled substance prescription registries.
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